Concepts (377)
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with CARLOS RAMOS's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that CARLOS RAMOS has written about over time.
T-Lymphocytes, CytotoxicIndoleamine-Pyrrole 2,3,-DioxygenaseHematologic NeoplasmsLymphoma, Non-HodgkinVidarabineImmunoglobulin kappa-ChainsHematopoietic Stem Cell TransplantationAntigens, CD19ImmunotherapyReceptors, Antigen, T-CellImmunotherapy, AdoptiveLymphomaT-LymphocytesHodgkin DiseaseCell- and Tissue-Based TherapyKi-1 AntigenDrug ApprovalLymphoma, T-CellSpectrum Analysis, Raman
To see the data from this visualization as text,
click here.
| Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
|---|
| T-Lymphocytes, Cytotoxic | 5 | 2009 | 2019 | October 2014 |
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 2015 | May 2015 |
| Hematologic Neoplasms | 4 | 2009 | 2022 | August 2015 |
| Lymphoma, Non-Hodgkin | 5 | 2011 | 2018 | January 2016 |
| Vidarabine | 3 | 2012 | 2020 | February 2016 |
| Immunoglobulin kappa-Chains | 1 | 2016 | 2016 | June 2016 |
| Hematopoietic Stem Cell Transplantation | 14 | 2009 | 2024 | October 2016 |
| Antigens, CD19 | 14 | 2010 | 2024 | December 2016 |
| Immunotherapy | 7 | 2009 | 2023 | May 2017 |
| Receptors, Antigen, T-Cell | 15 | 2011 | 2023 | February 2018 |
| Immunotherapy, Adoptive | 23 | 2011 | 2024 | August 2018 |
| Lymphoma | 10 | 2011 | 2024 | October 2018 |
| T-Lymphocytes | 26 | 2011 | 2024 | January 2019 |
| Hodgkin Disease | 6 | 2015 | 2023 | July 2019 |
| Cell- and Tissue-Based Therapy | 5 | 2017 | 2023 | July 2020 |
| Ki-1 Antigen | 3 | 2017 | 2023 | July 2020 |
| Drug Approval | 1 | 2021 | 2021 | January 2021 |
| Lymphoma, T-Cell | 2 | 2023 | 2024 | November 2023 |
| Spectrum Analysis, Raman | 1 | 2024 | 2024 | February 2024 |
To return to the timeline,
click here.